Related Experiment Video
Updated: May 4, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
Ovarian cancer stem cell-specific gene expression profiling and targeted drug prescreening
Yuting Huang1, Baohui Ju1, Jing Tian1
1Department of Gynecological Oncology, Tianjin Medical Univerisity Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.
Abstract:
Cancer stem cells, with unlimited self-renewal potential and other stem cell characteristics, occur in several types of cancer, including ovarian cancer (OvC). Although CSCs can cause tumor initiation, malignant proliferation, relapse and multi-drug resistance, ways to eliminate them remain unknown. In the present study, we compared ovarian cancer stem cell (OVCSC) expression profiles in normal ovarian surface epithelium and ovarian cells from patients with advanced disease to identify key pathways and specific molecular signatures involved in OVC progression and to prescreen candidate small-molecule compounds with anti-OVCSC activity. Comparison of genome-wide expression profiles of OvC stemness groups with non-stemness controls revealed 6495, 1347 and 509 differentially expressed genes in SDC, SP1 and SP2 groups, respectively, with a cut-off of fold-change set at >1.5 and P<0.05. NAB1 and NPIPL1 were commonly upregulated whereas PROS1, GREB1, KLF9 and MTUS1 were commonly downregulated in all 3 groups. Most differentially expressed genes consistently clustered with molecular functions such as protein receptor binding, kinase activity and chemo-repellent activity. These genes regulate cellular components such as centrosome, plasma membrane receptors, and basal lamina, and may participate in biological processes such as cell cycle regulation, chemoresistance and stemness induction. Key Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways such as ECM receptor, ErbB signaling, endocytosis and adherens junction pathways were enriched. Gene co-expression extrapolation screening by the Connectivity Map revealed several small-molecule compounds (such as SC-560, disulfiram, thapsigargin, esculetin and cinchonine) with potential anti-OVCSC properties targeting OVCSC signature genes. We identified several key CSC features and specific regulation networks in OVCSCs and predicted several small molecules with potential anti-OVCSC pharmacological properties, which may aid the development of OVCSC-specific drugs.
Insights
Researchers identified key molecular signatures in ovarian cancer stem cells (OVCSCs) to find new drugs. Several small molecules show potential for targeting and eliminating these resistant OVCSCs, offering hope for new ovarian cancer treatments.
Area of Science:
- Genomics and Molecular Biology
- Oncology
- Stem Cell Biology
Background:
- Ovarian cancer stem cells (OVCSCs) possess self-renewal and drive tumor initiation, relapse, and drug resistance.
- Effective strategies to eliminate OVCSCs are currently lacking.
- Understanding OVCSC molecular profiles is crucial for developing targeted therapies.
Purpose of the Study:
- To compare gene expression profiles of OVCSCs with normal ovarian cells and non-stem ovarian cancer cells.
- To identify molecular signatures and pathways involved in ovarian cancer progression and stemness.
- To prescreen small-molecule compounds with potential anti-OVCSC activity.
Main Methods:
- Genome-wide expression profiling of different ovarian cancer stemness groups (SDC, SP1, SP2) versus non-stemness controls.
- Differential gene expression analysis (fold-change >1.5, P<0.05).
- Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis.
- Gene co-expression extrapolation screening using the Connectivity Map.
Main Results:
- Identified 6495, 1347, and 509 differentially expressed genes in SDC, SP1, and SP2 groups, respectively.
- Commonly upregulated genes: NAB1, NPIPL1. Commonly downregulated genes: PROS1, GREB1, KLF9, MTUS1.
- Enriched KEGG pathways include ECM receptor, ErbB signaling, endocytosis, and adherens junction.
- Predicted small molecules like SC-560, disulfiram, thapsigargin, esculetin, and cinchonine show potential anti-OVCSC properties.
Conclusions:
- Key molecular signatures and regulatory networks in OVCSCs have been identified.
- Several small molecules demonstrate potential for targeting OVCSC-specific genes.
- These findings may facilitate the development of novel OVCSC-targeted drugs for ovarian cancer.

